Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.
Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.
The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.